SCHEMBL24469705

SCHEMBL24469705

COc1ccc(OC(C(=O)Cl)c2ccccc2Br)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.41
PPARA Q07869 2/20 0.41
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
TAS1R2 Q8TE23 1/20 0.40
ALDH1A1 P00352 1/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
CES2 O00748 2/20 0.39
CES1 P23141 2/20 0.39
KMT2A Q03164 6/20 0.39
MEN1 O00255 5/20 0.39
HTT P42858 1/20 0.38
MAPT P10636 2/20 0.38
RAB9A P51151 2/20 0.38
LMNA P02545 1/20 0.38
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24469704 0.87 PPARG (0.49) PPARGPPARATAS1R3TAS1R1TAS1R2
SCHEMBL24469703 0.85 ALDH1A1 (0.44) PPARGPPARATAS1R3TAS1R1TAS1R2
SCHEMBL24469712 0.80 GAA (0.46) PPARGPPARATAS1R3TAS1R1ALDH1A1
SCHEMBL31532232 0.80 GAA (0.46) PPARGPPARATAS1R3TAS1R1ALDH1A1
SCHEMBL24469706 0.72 HTT (0.44) ALDH1A1KMT2AMEN1HTTRAB9A
SCHEMBL24469943 0.72 HTT (0.44) ALDH1A1KMT2AMEN1HTTRAB9A
SCHEMBL5671557 0.70 TSHR (0.46) ALDH1A1MAPTRAB9ALMNAMAPK1
SCHEMBL30986705 0.70 TSHR (0.46) ALDH1A1MAPTRAB9ALMNAMAPK1
SCHEMBL3628345 0.69 CYP2C19 (0.46) ALDH1A1KMT2AHTTGAAL3MBTL1
SCHEMBL9780871 0.69 HTT (0.51) ALDH1A1HTTLMNAGAACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606549-B2 Anticholinergic agents REZUBIO PHARMACEUTICALS CO., LTD (CN) 2026-04-21 US disclosed
CN-116669721-B Anticholinergic agent 宁康瑞珠生物制药(珠海)有限公司 2025-03-18 CN disclosed
US-20240002372-A1 ANTICHOLINERGIC AGENTS REZUBIO PHARMACEUTICALS CO., LTD (CN) 2024-01-04 US disclosed
CN-116669721-A Anticholinergic agent 宁康瑞珠生物制药(珠海)有限公司 2023-08-29 CN disclosed
WO-2022111500-A1 ANTICHOLINERGIC AGENTS REZUBIO PHARMACEUTICALS CO., LTD (CN) 2022-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002372-A1 ANTICHOLINERGIC AGENTS CHRM3, CHRM2, CHRM1 PPARG 1848/4885PPARA 2559/4885TAS1R3 286/4885
US-12606549-B2 Anticholinergic agents CHRM1, CHRNA1, CHRND PPARG 2169/4885PPARA 3478/4885TAS1R3 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.